Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large… (NCT04668365) | Clinical Trial Compass
SuspendedPhase 2
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
Stopped: Data in analysis
China59 participantsStarted 2020-12-25
Plain-language summary
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of zanubrutinib combined with standard chemotherapy in the treatment for patients with diffuse large B cell lymphoma and CD79A/CD79B genetic abnormality.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age between 18 to 75 years old (including 18 and 75)
✓. Diagnosed as diffuse large B cell lymphoma
✓. CD79A/CD79B genetic abnormality
✓. Subjects with untreated or relapsed/refractory DLBCL
✓. Having at least one measurable lesions
✓. World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-1
✓. Life expectancy no less than 3 months
✓. enough main organ function
Exclusion criteria
✕. Diagnosed as high-grade B-cell lymphoma, including non-specified and double-strike or triple-strike
✕. Diagnosed as grey-zone lymphoma
✕. Diagnosed as primary mediastinal large B-cell lymphoma
✕. Diagnosed as CD20 negative diffuse large B-cell lymphoma
✕. Active malignant tumor need be treated at the same time
✕. Other malignant tumor history
✕. Serious surgery and trauma less than two weeks
What they're measuring
1
Proportion of complete remission for 3-4 weeks after induction treatment
Timeframe: from the date of the first cycle of treatment to 3-4 weeks after induction treatment of the last included patient (each cycle is 21 days)